… of immune checkpoint inhibitor (ICI) treatment for cancer … HLA-I evolutionary divergence
(HED) of patients with cancer … divergence between HLA-I alleles of each patient’s genotype. …

… However, tumor responses to these drugs are variable, and treatment resistance is common
(4–6). To date, most research to predict clinical efficacy … The combined effect of HLA class I …

… the impact of class I and class II human leukocyte antigen (HLA) genotypes, heterozygosity,
and diversity on the efficacy of … Association with HLA class I evolutionary divergence was …

… by the divergent allele advantage of the HLA-I genotype [18, 33]… of classic HLA class I genes
in GI cancer and investigate their … effects of both zygosity and HED at the HLA-A, HLA-B and …

… We describe the high clinical efficacy and its genomic … As described previously, HLA-I
genotyping of blood-derived … of quantifying the overall evolutionary divergence at the HLA class-I …

… In this study, we integrated clinical and HLA-I genotype data of … III trial to investigate the
efficacy and safety of camrelizumab or … the effect of HED of HLA-A, HLA-B, or HLA-C on treatment …

… with more divergent HLA class I alleles could respond better to … In fact, HLA class I and class
II genotypes have been shown … inconsistent immunotherapy efficacy across cancer cohorts …

… germline HLA-I diversity strongly impacted treatment efficacy. … that HLA genotype can affect
ICB response[31, 47]. Reduced … the overall evolutionary divergence at the HLA class-I alleles[…

… total number of heterozygous genotypes at HLA class I and/or … a potential complementary
effect of HLA class I and class II … tumor types failed to report HLA evolutionary divergence as …

… we assess the implications for current immunotherapy approaches … inferred that HLA LOH
was a late event in tumor evolution and … Most studies focus on how to increase the efficiency of …